Companies

BioNTech

5 articles

Industry NewsBioNTech / Scholar RockEndpoints News

BioNTech pays $205M for Scholar Rock’s rare pediatric priority review voucher

  • Scholar Rock’s SEC filing says a buyer will pay $205M cash at closing for its Rare Pediatric Disease Priority Review Voucher; German outlets identify BioNTech as the buyer.
  • Closing is subject to customary conditions, including antitrust clearance.
  • BioNTech reportedly plans to use the voucher for an unnamed late-stage oncology candidate.
PointsBased on public reports

A voucher cuts a standard FDA review down to roughly six months, so $205M is effectively the price of time on a drug whose peak sales justify it. For BioNTech it is a cheap way to pull forward a launch while it cuts costs elsewhere; for Scholar Rock it is non-dilutive cash. Voucher prices that hold this high suggest supply stays scarce, which matters for any small rare-disease biotech planning around a sale.

Industry NewsBioNTech / DualityBioEndpoints News

BioNTech and DualityBio's HER2 ADC wins a 'modest' Phase 3 in HR+/HER2-low breast cancer

  • The global Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan met its primary progression-free survival endpoint against physician's-choice chemotherapy.
  • Patients had chemotherapy-naive, HR+/HER2-low metastatic breast cancer that progressed on endocrine therapy.
  • The companies themselves call the benefit statistically significant but modest; overall survival data are still immature, and they are weighing next steps.
PointsBased on public reports

When the sponsors call their own win 'modest' in HER2-low, where Enhertu is the benchmark, they are signalling that this ADC will not displace it on efficacy. The more realistic path is a narrower niche or combinations, and the choice of next step will show how much BioNTech still wants to carry a HER2 ADC next to its bispecific bets.

Industry NewsBioNTech / GenentechEndpoints News

BioNTech, Genentech Terminate Phase 2 Trial of mRNA Cancer Vaccine Autogene Cevumeran in Colorectal Cancer

  • Autogene cevumeran is an individualized, tumor-specific neoantigen mRNA vaccine designed to trigger a T-cell response against a patient's unique tumor mutations.
  • Phase 2 trial BNT122-01, run with Genentech, evaluated it as adjuvant monotherapy versus watchful waiting in ctDNA-positive patients with surgically resected Stage II (high-risk) or Stage III colorectal cancer, targeting roughly 327 enrollees with disease-free survival as the primary endpoint.
  • BioNTech and Genentech terminated the trial on August 28, 2026, after an independent Data Safety Monitoring Board (DSMB) identified a numerical overall-survival imbalance disfavoring the vaccine arm and concluded continuation was unlikely to change the efficacy outcome; no new safety signals were found.
  • A separate, unaffected Phase 2 trial (Imcode003) continues to evaluate autogene cevumeran combined with checkpoint inhibition and chemotherapy in adjuvant pancreatic ductal adenocarcinoma.
  • BioNTech shares fell as much as 8% on the news.
PointsBased on public reports

An OS imbalance with no new safety signal is a different failure mode than a safety-driven halt — it indicts adjuvant monotherapy in CRC, not necessarily neoantigen mRNA vaccines as a modality. That distinction matters competitively: Moderna/Merck's V940 (INT) has paired its individualized vaccine with pembrolizumab from the outset rather than testing it solo against watchful waiting, and BioNTech's own still-running pancreatic trial (Imcode003) uses that same vaccine-plus-checkpoint-inhibitor-plus-chemo architecture. So the part of the platform that just failed is arguably its least mechanistically ambitious use case. The 8% single-day drop on one Phase 2 readout, though, is the bigger tell — it shows how much of BioNTech's valuation still rests on individualized-vaccine optionality rather than de-risked, validated pipeline.

Industry NewsBioNTech / OncoC4Fierce Biotech

BioNTech's CTLA-4 Drug Nearly Doubles Survival in Lung Cancer Trial, But Raises Tolerability Concerns

  • Gotistobart (BNT316/ONC-392), a CTLA-4-targeting monoclonal antibody from BioNTech and partner OncoC4, is designed to selectively deplete regulatory T cells within the tumor microenvironment.
  • Updated stage 1 data from the global Phase 3 PRESERVE-003 trial were presented at the IASLC 2026 World Conference on Lung Cancer.
  • The trial enrolled previously treated metastatic squamous non-small cell lung cancer (NSCLC) patients whose disease had progressed on prior immunotherapy and chemotherapy.
  • Gotistobart nearly doubled median overall survival to 18.5 months versus 10.0 months for docetaxel chemotherapy, a statistically significant and clinically meaningful benefit (hazard ratio 0.56).
  • Fierce Biotech's coverage noted the drug poses a tolerability challenge alongside this survival benefit.
  • The pivotal stage 2 portion of PRESERVE-003 is ongoing at more than 160 sites worldwide.
PointsBased on public reports

CTLA-4 carries baggage — ipilimumab's toxicity effectively exiled the class to combo-backup duty, so gotistobart's whole pitch is "selective Treg depletion solves what ipi couldn't." A tolerability flag showing up in the very same headline as the efficacy win is the tension to watch, not a footnote. That said, nearly doubling median OS (18.5 vs 10.0 months, HR 0.56) in post-IO/chemo squamous NSCLC is a genuinely hard bar to clear — this is BioNTech's most credible non-mRNA oncology proof point yet, a real diversification lever beyond the vaccine franchise. It's also OncoC4's asset first: a clean stage 2 readout would meaningfully strengthen OncoC4's hand on deal economics with BioNTech, not just validate the science. Market-wise, the OS number is a legitimate re-rating catalyst, but "tolerability concerns" in the same breath keeps enthusiasm capped until discontinuation and grade 3+ rates surface from the pivotal cohort.

Industry NewsBioNTech / OncoC4Fierce Biotech

BioNTech/OncoC4's Gotistobart Nearly Doubles Survival in Hard-to-Treat Lung Cancer Ahead of Pivotal Readout

  • BioNTech and OncoC4 reported stage 1 overall-survival data from the phase 3 PRESERVE-003 trial in metastatic squamous NSCLC, ahead of the pivotal stage 2 readout.
  • Gotistobart (BNT316/ONC-392) is a pH-sensitive anti-CTLA-4 antibody designed to selectively deplete regulatory T cells in the tumor microenvironment, a differentiated mechanism versus conventional CTLA-4 blockers like ipilimumab.
  • In 87 randomized patients who had progressed on prior PD-(L)1 and platinum chemotherapy, median overall survival nearly doubled: 18.5 months with gotistobart versus 10.0 months with docetaxel (HR 0.56).
  • Grade ≥3 treatment-related adverse events were similar between arms (44.4% vs 48.8%), with a manageable safety profile.
  • Pivotal stage 2, with overall survival as the primary endpoint, is now underway at 160+ global sites.
PointsBased on public reports

The differentiator here is mechanism, not just efficacy: a pH-selective, tumor-restricted Treg-depletion approach delivering a near-doubling of OS over docetaxel with grade ≥3 toxicity roughly flat to chemo is the tolerability profile ipilimumab-based regimens have never cleared — that's the real competitive wedge against BMS's checkpoint franchise and every less-selective CTLA-4 follower. Eighty-seven patients and an HR of 0.56 is directional, not confirmatory, but it's a strong enough signal in a chemo-refractory population with no compelling 2L+ standard to justify running 160+ sites into stage 2 ahead of topline data. Bigger picture: this is BioNTech executing its post-COVID pivot — building a wholly-owned, mechanistically differentiated oncology franchise rather than leaning on mRNA vaccine partnerships. A pivotal win makes gotistobart the company's first major non-mRNA solid-tumor asset with real blockbuster optionality.